Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group.

To test the anti-tumour activity of rhizoxin in recurrent and/or metastatic squamous cell head and neck cancer, we performed a phase II study. Eligibility required histologically proven squamous cell head and neck cancer. Patients could only have received one prior chemotherapy. Patients were entere...

Descripción completa

Detalles Bibliográficos
Autores principales: Verweij, J., Wanders, J., Gil, T., Schöffski, P., Catimel, G., te Velde, A., de Mulder, P. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074424/
https://www.ncbi.nlm.nih.gov/pubmed/8562350
_version_ 1782137963755339776
author Verweij, J.
Wanders, J.
Gil, T.
Schöffski, P.
Catimel, G.
te Velde, A.
de Mulder, P. H.
author_facet Verweij, J.
Wanders, J.
Gil, T.
Schöffski, P.
Catimel, G.
te Velde, A.
de Mulder, P. H.
author_sort Verweij, J.
collection PubMed
description To test the anti-tumour activity of rhizoxin in recurrent and/or metastatic squamous cell head and neck cancer, we performed a phase II study. Eligibility required histologically proven squamous cell head and neck cancer. Patients could only have received one prior chemotherapy. Patients were entered if WHO PS was < or = 2 and organ functions were normal. Treatment consisted of rhizoxin 1.5-2.0 mg m-2 i.v. bolus injection once every 3 weeks. Thirty-two patients entered the study. All were eligible, 31 were evaluable for toxicity and 25 for response. Toxicity mainly consisted of pain at the tumour site and leucocytopenia. Mild asthenia and stomatitis were also observed. Two objective partial responses, lasting 7.5 and 3.5 months, were seen. Rhizoxin at this dose and schedule has minor activity in recurrent and/or metastatic squamous cell head and neck cancer.
format Text
id pubmed-2074424
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20744242009-09-10 Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group. Verweij, J. Wanders, J. Gil, T. Schöffski, P. Catimel, G. te Velde, A. de Mulder, P. H. Br J Cancer Research Article To test the anti-tumour activity of rhizoxin in recurrent and/or metastatic squamous cell head and neck cancer, we performed a phase II study. Eligibility required histologically proven squamous cell head and neck cancer. Patients could only have received one prior chemotherapy. Patients were entered if WHO PS was < or = 2 and organ functions were normal. Treatment consisted of rhizoxin 1.5-2.0 mg m-2 i.v. bolus injection once every 3 weeks. Thirty-two patients entered the study. All were eligible, 31 were evaluable for toxicity and 25 for response. Toxicity mainly consisted of pain at the tumour site and leucocytopenia. Mild asthenia and stomatitis were also observed. Two objective partial responses, lasting 7.5 and 3.5 months, were seen. Rhizoxin at this dose and schedule has minor activity in recurrent and/or metastatic squamous cell head and neck cancer. Nature Publishing Group 1996-02 /pmc/articles/PMC2074424/ /pubmed/8562350 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Verweij, J.
Wanders, J.
Gil, T.
Schöffski, P.
Catimel, G.
te Velde, A.
de Mulder, P. H.
Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group.
title Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group.
title_full Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group.
title_fullStr Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group.
title_full_unstemmed Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group.
title_short Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group.
title_sort phase ii study of rhizoxin in squamous cell head and neck cancer. the eortc early clinical trials group.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074424/
https://www.ncbi.nlm.nih.gov/pubmed/8562350
work_keys_str_mv AT verweijj phaseiistudyofrhizoxininsquamouscellheadandneckcancertheeortcearlyclinicaltrialsgroup
AT wandersj phaseiistudyofrhizoxininsquamouscellheadandneckcancertheeortcearlyclinicaltrialsgroup
AT gilt phaseiistudyofrhizoxininsquamouscellheadandneckcancertheeortcearlyclinicaltrialsgroup
AT schoffskip phaseiistudyofrhizoxininsquamouscellheadandneckcancertheeortcearlyclinicaltrialsgroup
AT catimelg phaseiistudyofrhizoxininsquamouscellheadandneckcancertheeortcearlyclinicaltrialsgroup
AT teveldea phaseiistudyofrhizoxininsquamouscellheadandneckcancertheeortcearlyclinicaltrialsgroup
AT demulderph phaseiistudyofrhizoxininsquamouscellheadandneckcancertheeortcearlyclinicaltrialsgroup

Ejemplares similares